The new version of the Galen platform is said to advance the diagnosis of prostate, breast and gastric cancer and includes expanded detection, user interface, and workflow integration capabilities
Ibex rolls out new cancer diagnostics platform. (Credit: CDC on Unsplash)
Israel-based Ibex Medical Analytics has rolled out its new-generation solution, Galen 3.0, for the detection and diagnosis of multiple tissue types across various digital pathology workflows.
Galen 3.0 has advanced versions of Ibex’ AI algorithms for the detection of cancer and other clinically relevant features in the prostate, breast, and gastric biopsies.
It was recently granted the CE mark and supports the review of breast, prostate, and gastric biopsies, to help pathologists improve the quality of cancer diagnosis.
The company trained the Deep Learning networks on large data sets from laboratories that were digitised by multiple scanning systems, including rare prostatic malignancies.
In addition, Galen 3.0 calculates a Gleason score, which describes the tumour size and percentage for each cancer slide, to help pathologists by reducing review time.
It comes with an open API accelerating interoperability and can be easily integrated with imaging solutions, lab information systems and digital pathology workflow solutions.
The latest version of Galen includes new customisable reporting modules and enables customised slide and case reports as per patients’ needs, said Ibex.
Ibex product management vice president Issar Yazbin said: “We are excited to bring Galen 3.0 to pathology labs worldwide, providing clinically validated, automated decision-support tools that help pathologists diagnose cancer more rapidly and more accurately to support the high demand.
“Keeping our customers’ needs central to our research and development, we are proud to deploy Galen 3.0, bringing enhanced detection capabilities, improved user experience, increased interoperability tools and ease of implementation into existing clinical workflows.”
In a separate development, Ibex has teamed up with Medipath, one of the large-scale private pathology lab networks in France.
Medipath provides pathology services to more than 250 hospitals and clinics in the country, with a network of 115 pathologists and more than 580 employees.
The two companies signed an agreement to expand their partnership for the deployment of Ibex’s AI solutions to additional labs in the Medipath network.
Under the expanded partnership, Ibex will deploy its AI-powered diagnostic tools for multiple tissue types, across all Medipath sites in France.
Pathologists at Medipath can use the Galen platform for decision support during primary diagnosis of breast, prostate and gastric biopsies, with accuracy and simplified workflows.
With the network-level AI implementation at scale, Medipath will benefit from reduced operational costs and improved service levels.
Medipath group chairman Olivier Vire said: “We are writing a new chapter on our digital transformation journey, and excited to work with our partners at Ibex on this expansion project, making their AI portfolio available to more labs and pathologists in our network.
“Integrating Ibex as a foundation of primary diagnosis helps our pathologists improve the accuracy of reporting and optimise processes in our labs that ultimately deliver better patient care.
“We look forward to introducing additional AI tools from Ibex across our network as Medipath remains committed to being the leading AI-enabled healthcare provider in France.”